Serous cystadenocarcinoma

Summary

Serous cystadenocarcinoma (MONDO:0024621) is a disease and 4 clinical trials. Top therapeutic interventions include ipilimumab. A subtype of serous adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	serous cystadenocarcinoma
Mondo ID	MONDO:0024621
NCIT	C3778
UMLS	C0206701
MedGen	60212
Is cancer (heuristic)	no

Also known as: serous adenocarcinoma · serous cystadenocarcinoma

Disease family

This is a subtype of serous adenocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › serous adenocarcinoma › serous cystadenocarcinoma

Related subtypes (5): peritoneal serous adenocarcinoma, cervical serous adenocarcinoma, ovarian serous adenocarcinoma, endometrial serous adenocarcinoma, fallopian tube serous adenocarcinoma

Subtypes (3): papillary serous cystadenocarcinoma, pancreatic serous cystadenocarcinoma, ovarian serous cystadenocarcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2/PHASE3	1
PHASE2	1
EARLY_PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04055038	PHASE2/PHASE3	UNKNOWN	Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)
NCT02834013	PHASE2	ACTIVE_NOT_RECRUITING	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT05289648	EARLY_PHASE1	WITHDRAWN	Niraparib in High-grade Endometrial Cancer Trial
NCT03150121	Not specified	UNKNOWN	Biomarkers for Early Detection of Ovarian Cancer Using Uterine Lavage

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
IPILIMUMAB	4	1